{"id":137700,"date":"2022-01-17T07:25:50","date_gmt":"2022-01-17T05:25:50","guid":{"rendered":"https:\/\/tietopankki.crnet.fi\/fi\/news\/who-recommends-two-new-drugs-to-treat-patients-with-covid-19\/"},"modified":"2022-01-17T07:25:50","modified_gmt":"2022-01-17T05:25:50","slug":"who-recommends-two-new-drugs-to-treat-patients-with-covid-19","status":"publish","type":"post","link":"https:\/\/tietopankki.crnet.fi\/fi\/news\/who-recommends-two-new-drugs-to-treat-patients-with-covid-19\/","title":{"rendered":"WHO recommends\u202ftwo\u202fnew drugs to treat patients with COVID-19\u202f\u202f"},"content":{"rendered":"<div class=\"mp_wrapper\">\n  <div class=\"mepr-unauthorized-message\">\n    <p>You are unauthorized to view this page.<\/p>\n  <\/div>\n  <div class=\"mepr-login-form-wrap\">\n            \n<div class=\"mp_wrapper mp_login_form\">\n                  <!-- mp-login-form-start -->     <form name=\"mepr_loginform\" id=\"mepr_loginform\" class=\"mepr-form\" action=\"https:\/\/tietopankki.crnet.fi\/fi\/login-2\/\" method=\"post\">\n            <div class=\"mp-form-row mepr_username\">\n        <div class=\"mp-form-label\">\n                              <label for=\"user_login\">Username<\/label>\n        <\/div>\n        <input type=\"text\" name=\"log\" id=\"user_login\" value=\"\" \/>\n      <\/div>\n      <div class=\"mp-form-row mepr_password\">\n        <div class=\"mp-form-label\">\n          <label for=\"user_pass\">Password<\/label>\n          <div class=\"mp-hide-pw\">\n            <input type=\"password\" name=\"pwd\" id=\"user_pass\" value=\"\" \/>\n            <button type=\"button\" class=\"button mp-hide-pw hide-if-no-js\" data-toggle=\"0\" aria-label=\"Show password\">\n              <span class=\"dashicons dashicons-visibility\" aria-hidden=\"true\"><\/span>\n            <\/button>\n          <\/div>\n        <\/div>\n      <\/div>\n            <div>\n        <label><input name=\"rememberme\" type=\"checkbox\" id=\"rememberme\" value=\"forever\" \/> Remember Me<\/label>\n      <\/div>\n      <div class=\"mp-spacer\">&nbsp;<\/div>\n      <div class=\"submit\">\n        <input type=\"submit\" name=\"wp-submit\" id=\"wp-submit\" class=\"button-primary mepr-share-button \" value=\"Log In\" \/>\n        <input type=\"hidden\" name=\"redirect_to\" value=\"\/fi\/wp-json\/wp\/v2\/posts\/137700\" \/>\n        <input type=\"hidden\" name=\"mepr_process_login_form\" value=\"true\" \/>\n        <input type=\"hidden\" name=\"mepr_is_login_page\" value=\"false\" \/>\n      <\/div>\n    <\/form>\n    <div class=\"mp-spacer\">&nbsp;<\/div>\n    <div class=\"mepr-login-actions\">\n        <a\n          href=\"https:\/\/tietopankki.crnet.fi\/fi\/login-2\/?action=forgot_password\"\n          title=\"Click here to reset your password\"\n        >\n          Forgot Password        <\/a>\n    <\/div>\n\n      \n    <!-- mp-login-form-end --> \n  <\/div>\n      <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<div class=\"smart_content_wrapper\">\n<p>&nbsp;<\/p>\n<p>The World Health Organization (WHO) recommended on Thursday two new drugs to treat patients with COVID-19, one for patients with critical diseaseand one for non-severe cases. The first drug, baricitinib, is a Janus kinase (JAK) inhibitor- a class of drugs used to treat autoimmune conditions, blood and bone marrow cancers, and rheumatoid arthritis. According to the WHO Guideline Development Group, it is \u201cstrongly recommended\u201d for patients with severe or critical disease in combination with corticosteroids.<\/p>\n<p>The group of international experts based their recommendation on \u201cmoderate certainty evidence\u201d that it improves survival and reduces the need for ventilation. There was no observed increase in adverse effects. The experts note that it has a similar effectas other arthritis drugs called interleukin-6 (IL-6) inhibitors. Because of that, when both drugs are available, they suggest choosing the best option based on cost, availability, and clinician experience.<\/p>\n<p>It is not recommended to use both drugs at the same time. The experts also advise against the use of\u202ftwo\u202fother JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical cases of COVID-19 infection. According to them, trials undergone using these drugs failed to show any benefits arising using either drug,and suggested a possible increase in serious side effects with tofacitinib.<\/p>\n<p>In the same update, WHO makes a conditional recommendation for the use of a monoclonal antibody known as so trovimab in patients with non-severe cases. According to them, the drug should only be administered to patients at the highest risk of hospitalisation. In those at lower risk, it only showed \u201ctrivial benefits\u201d. A similar recommendation has been made previously, for another monoclonal antibody drug, casirivimab-imdevimab, and the experts say there is insufficient data to recommend one over the other. The group will update their guidelines for monoclonal antibodies when more data becomes available.<\/p>\n<p>These recommendations are based on new evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical infections. Developed by WHO with the methodological support of MAGIC Evidence Ecosystem Foundation, the guidelines provide trustworthy guidance and help doctors make better decisions with their patients. According to the agency, the guidelines are useful in fast moving research areas, because they allow researchers to update evidence summaries as new information becomes available.<\/p>\n<p>Source: <a rel=\"noopener\" href=\"https:\/\/news.un.org\/en\/story\/2022\/01\/1109722\">The UN<\/a><\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<p>The post <a rel=\"noopener\" href=\"https:\/\/vastuullisuusuutiset.fi\/fi\/csr-news-en\/who-recommends%e2%80%aftwo%e2%80%afnew-drugs-to-treat-patients-with-covid-19%e2%80%af%e2%80%af-2\/\">WHO recommends\u202ftwo\u202fnew drugs to treat patients with COVID-19\u202f\u202f<\/a> appeared first on <a rel=\"noopener\" href=\"https:\/\/vastuullisuusuutiset.fi\/fi\">Vastuullisuusuutiset.fi<\/a>.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[22],"tags":[1063,555,4754,18062,8461,432],"class_list":["post-137700","post","type-post","status-publish","format-standard","hentry","category-news","tag-covid-19","tag-csr-news-en","tag-patient","tag-two-new-drugs","tag-weeks-highlights","tag-who"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/posts\/137700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/comments?post=137700"}],"version-history":[{"count":0,"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/posts\/137700\/revisions"}],"wp:attachment":[{"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/media?parent=137700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/categories?post=137700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tietopankki.crnet.fi\/fi\/wp-json\/wp\/v2\/tags?post=137700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}